Latest Period
Q1 2026
Security Snapshot
SUTRO BIOPHARMA, INC. - Common Stock, $0.001 par value (STRO) Institutional Ownership
CUSIP: 869367201
13F Institutional Holders and Ownership History from Q4 2025 to Q1 2026
Institutions Reporting
69
Shares (Excl. Options)
14,095,307
Price
$24.91
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, $0.001 par value
- Symbol
- STRO on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 14,095,307
- Total 13F value
- $351,112,986
- Portfolio coverage rank
- 0%
- Share change
- +8,339,717
- Value change
- +$214,425,468
- Number of holders
- 69
- Shares outstanding
- 16,470,895
- SEC-reported price per share
- $40.24
- Insider filing price
- $40.24
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- STRO - SUTRO BIOPHARMA, INC. - Common Stock, $0.001 par value is tracked under CUSIP 869367201.
- 69 institutions reported positions in Q1 2026.
- 2 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 54 to 69 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $61,441,352 to $351,112,986.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 69 institutions filings for Q1 2026.
Security key
869367201
Latest holder period
Q1 2026
13F holders
69
13D/G owners
2
CIK / CUSIP context first
Open Q1 2026 holders
STRO full holder history
SUTRO BIOPHARMA, INC. SEC filings
SUTRO BIOPHARMA, INC. company facts
SUTRO BIOPHARMA, INC. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 869367201:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
2
Security
STRO
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| BIOTECHNOLOGY VALUE FUND L P | 7.6% | $13,306,506 | 1,251,788 | BVF PARTNERS L P/IL | 10 Feb 2026 | |||
| Affinity Asset Advisors, LLC | 8.8% | $8,444,817 | 748,382 | Affinity Asset Advisors, LLC | 22 Jan 2026 |
As of 31 Mar 2026, 69 institutional investors reported holding 14,095,307 shares of SUTRO BIOPHARMA, INC. - Common Stock, $0.001 par value (STRO). This represents 86% of the company’s total 16,470,895 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
80%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| BVF INC/IL | 7.6% | 1,251,788 | 0.99% | $31,182,039 | |
| Affinity Asset Advisors, LLC | 6.5% | 1,069,519 | +43% | 1.6% | $26,641,718 |
| SAMSARA BIOCAPITAL, LLC | 6.5% | 1,062,872 | +420% | 2.6% | $26,476,142 |
| Kynam Capital Management, LP | 5.3% | 872,558 | +82% | 1.4% | $21,735,420 |
| ORBIMED ADVISORS LLC | 4.9% | 801,144 | 0.45% | $19,956,497 | |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.4% | 720,442 | 0% | 0% | $17,946,210 |
| PERCEPTIVE ADVISORS LLC | 4.3% | 715,307 | 0.35% | $17,818,297 | |
| RA CAPITAL MANAGEMENT, L.P. | 4.3% | 715,307 | 0.19% | $17,818,297 | |
| EVENTIDE ASSET MANAGEMENT, LLC | 4.3% | 715,307 | 0.29% | $17,818,297 | |
| Point72 Asset Management, L.P. | 4.2% | 692,111 | +286% | 0.03% | $17,240,485 |
| ADAR1 Capital Management, LLC | 3.2% | 524,441 | +682% | 0.79% | $13,063,825 |
| Velan Capital Investment Management LP | 3.1% | 512,160 | +64% | 8% | $12,757,906 |
| Balyasny Asset Management L.P. | 2.8% | 465,792 | +102% | 0.02% | $11,602,879 |
| Woodline Partners LP | 2.8% | 457,441 | 0.04% | $11,394,855 | |
| UBS Group AG | 2.4% | 392,871 | +4892% | 0% | $9,786,416 |
| ACADIAN ASSET MANAGEMENT LLC | 2% | 335,813 | -0.63% | 0.01% | $8,363,000 |
| ACUTA CAPITAL PARTNERS, LLC | 1.6% | 269,425 | +299% | 4.8% | $6,711,377 |
| BlackRock, Inc. | 1.4% | 232,684 | +98% | 0% | $5,796,159 |
| KVP Capital Advisors, LP | 1.4% | 226,575 | 4.2% | $5,643,983 | |
| MARSHALL WACE, LLP | 1.4% | 222,634 | +160% | 0.01% | $5,545,813 |
| MILLENNIUM MANAGEMENT LLC | 1.3% | 210,378 | -50% | 0% | $5,240,516 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 1.2% | 200,000 | 0% | 0.01% | $4,982,000 |
| Opaleye Management Inc. | 1.2% | 190,671 | 0% | 0.66% | $4,749,615 |
| GEODE CAPITAL MANAGEMENT, LLC | 1% | 171,386 | +104% | 0% | $4,272,147 |
| CITADEL ADVISORS LLC | 0.71% | 117,537 | +266% | 0% | $2,927,847 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
2
Latest
Q1 2026
Rows shown
1-2 of 2